Roe D and Campbell T. Drugs and nutrients: The interactive effects. New York: Marcel Dekker, Inc., 1984: 479.
Choi YK, Han IK, and Yoon HK. Ipriflavone for the treatment of osteoporosis.
Osteoporos Int
7(Suppl. 3): S174-S178, 1997.
de Aloysio D, Gambacciani M, Altieri P, et al. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
Gynecol Endocrinol
11: 289 - 293, 1997.
Gambacciani M, Ciaponi M, Cappagli B, et al.
Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Maturitas
28(1): 75 - 81, 1997.
Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogen in the prevention of bone mineral loss in climacterium.
Bone Miner
19: S49 - S56, 1992.
Nozaki M, Hashimoto K, et al. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
Int J Gyn Ob
62: 69 - 75, 1998.
Petilli M, et al. Interactions between ipriflavone and the estrogen receptor.
Calcif Tissue Int
56: 160 - 165, 1995.
Cecchini MG, et al. Ipriflavone inhibits bone resorption in intact and ovariectomized rats.
Calcif Tissue Int
61: S9-S11, 1997.
Rivers JM and Devine M. Plasma ascorbic acid concentrations and oral contraceptives.
Am J Clin Nutr
25: 684 - 689, 1972.
Pronsky Z, ed. Powers and Moore's food medication interactions, 10th ed. Pottstown, PA: Food-Medication Interactions, 1997: 99.
Nielsen FH, Hunt CD, Mullen LM, and Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women.
FASEB J
1: 394 - 397, 1987.
Naghii and Samman S. The effect of boron supplementation on its urinary excretion and selected cardiovascular risk factors in healthy male subjects.
Biol Trace Elem Res
56(3): 273 - 286, 1997.
Meng Q, Yuan F, Goldberg ID, et al. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells.
J Nutr. 2000;130:2927 - 293l.
Gehm BD, McAndrews JM, Chien PY, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor.
Proc Natl Acad Sci U S A
94: 14138 - 14143, 1997.
Wilbur P. The phyto-oestrogen debate.
Eur J Herbal Med
2: 20 - 26, 1996.
Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial.
Fertil Steril
68: 981 - 986, 1997.
Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol.
Int J Obes Relat Metab Disord.
1998;22:227 - 229.
Bradlow HL, Sepkovic DW, Telang NT, et al. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent.
Ann N Y Acad Sci.
1999;889:204 - 213.
Yuan F, Chen DZ, Liu K, et al. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer.
Anticancer Res.
1999;19:1673 - 1680.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.